Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6745871 | 0.74 | POLB (0.57) | POLBSMN1; SMN2TSHRAPOBEC3AAPOBEC3G | |
| SCHEMBL13841319 | 0.70 | POLB (0.65) | POLBSMN1; SMN2TSHRAPOBEC3AAPOBEC3G | |
| SCHEMBL933508 | 0.68 | HTR3A (0.42) | — | |
| SCHEMBL1499360 | 0.67 | PSIP1 (0.39) | APOBEC3GMAPTNPSR1 | |
| SCHEMBL3936569 | 0.67 | POLB (1.00) | POLBSMN1; SMN2TSHRAPOBEC3AAPOBEC3G | |
| SCHEMBL4234752 | 0.67 | HRH4 (0.47) | POLBSMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL8131529 | 0.66 | NAPRT (0.41) | POLBSMN1; SMN2TSHRHTTMAPT | |
| SCHEMBL3875830 | 0.66 | ALDH1A1 (0.33) | POLBSMN1; SMN2TSHRATMHTT | |
| SCHEMBL6280841 | 0.66 | — | — | |
| SCHEMBL14183920 | 0.66 | L3MBTL1 (0.71) | SMN1; SMN2TSHRMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3732180-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | Emory University (US) | 2020-11-04 | — | — | EP | claimed |
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | EMORY UNIVERSITY | 2021-03-04 | — | — | US | disclosed |
| EP-3732180-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | Emory University (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10772891-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2020-09-15 | — | — | US | disclosed |
| US-20180235976-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2018-08-23 | — | — | US | disclosed |
| US-9974791-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-05-22 | — | — | US | disclosed |
| EP-2860179-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-03-14 | — | — | EP | disclosed |
| EP-2674160-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-20150290208-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2015-10-15 | — | — | US | disclosed |
| US-9096588-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-08-04 | — | — | US | disclosed |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-21 | — | — | US | disclosed |
| EP-2344492-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2011-07-20 | — | — | EP | disclosed |
| EP-2344493-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2011-07-20 | — | — | EP | disclosed |
| US-20110172266-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-07-14 | — | — | US | disclosed |
| WO-2010035219-A2 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010035221-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010035217-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-04-01 | — | — | WO | disclosed |
| EP-2165707-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYO TEX SA (CH) | 2010-03-24 | — | — | EP | disclosed |
| EP-2166008-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYO TEX SA (CH) | 2010-03-24 | — | — | EP | disclosed |
| EP-2166010-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYO TEX SA (CH) | 2010-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290208-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | POLB 777/4885SMN1; SMN2 2521/4885TSHR 3255/4885 |
| US-20110172266-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | POLB 777/4885SMN1; SMN2 2521/4885TSHR 3255/4885 |
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | NOX1, NOX3, NOX4 | POLB 917/4885SMN1; SMN2 1676/4885TSHR 4751/4885 |
| US-20110178081-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | POLB 777/4885SMN1; SMN2 2521/4885TSHR 3255/4885 |
| US-20180235976-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | POLB 777/4885SMN1; SMN2 2521/4885TSHR 3255/4885 |
| US-10772891-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | NOX1, NOX4, CYBB | POLB 777/4885SMN1; SMN2 2521/4885TSHR 3255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.